gp130/IL6ST Protein, Human (HEK293)
Based on 1 Customer Validation
Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family. gp130 inhibits the cell growth and migration, decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity. gp130/IL6ST Protein, Human (HEK293) is a recombinant protein consisting of 596 amino acids (M23-I618) and is produced by HEK293 cells.
- Species: Human
- Source: HEK293
-
Storage:Stored at -80°C for 1 year from date of receipt. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- References
- Help & FAQs
Biological Activity
Description
Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family[1]. gp130 inhibits the cell growth and migration[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity[4][5]. gp130/IL6ST Protein, Human (HEK293) is a recombinant protein consisting of 596 amino acids (M23-I618) and is produced by HEK293 cells.
Background
Glycoprotein 130 (gp130) mRNA is ubiquitously expressed in the human body,exhibiting highest levels in saphenous vein, pericardium, ovary, omental adipose tissue, peritoneum, spleen lymphnodes, and trigeminal ganglia. And gp130 expression is significantly increased in adult organs compared to fetal organs. Moreover, gp130 is highly expressed in multiple types of cancers compared to normal tissues[3].
The amino acid sequence of human gp130 protein has low homology between mouse and rat gp130 protein.
gp130 signaling is initiated when autocrine or paracrine cyto-kines induce the dimerization of gp130 and an α-receptor subunit to form the receptor complex, leading to185the activation of downstream signaling cascades, such as the JAK/STAT, the PI3K/Akt, and the Ras/Raf/Mek/Erk1/2MAPK pathways. The activation of JAK/Stat3 pathway induces its target gene expression, resulting in cell growth and proliferation (cyclin D, CDC25 A, c-Myc, survivin), survival (survivin, Bcl-2, Bcl-XL), angiogenesis (VEGF), and cell migration (MMP-2, MMP-7, and MMP-9)[3].
gp130 is a IL-6 antagonist shows anti-tumor, anti-inflammation and antinociceptive activity[4]. gp130 decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67[5].
In Vitro
gp130 (human) (-1.14 µg/mL; 24 h) inhibits the cell growth in a dose-dependent manner and induces apoptosis in HepG2 cells[5].
gp130 (human) (-2 ng/mL; 48 h) significantly decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67 in HepG2 cells[5].
In Vivo
gp130 (human) (5 µg/mL; i.p., 2 µL; every third day for 12 days) shows antinociceptive effect in antigen-induced arthritis rats[4].
gp130 (human) (2 µg/mL; i.a.; 5 µL; every third day for 12 days) shows antinociceptive effect in antigen-induced arthritis rats[4].
gp130 (human) (1.14 µg/kg; i.v.; every 3 days for 35 days) suppresses tumor growth in NOD/SCID mice with HepG2 cells injection[5].
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag Tag Free
-
Accession
P40189-1/NP_002175.2 (E23-I618)
-
Molecular Construction
-
N-term
-
gp130 (E23-I618)
Accession # P40189-1/NP_002175.2 -
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
IL6ST; Interleukin Receptor Beta Chain; Interleukin 6 Cytokine Family Signal Transducer; Membrane Glycoprotein Gp130; Interleukin-6 Receptor Subunit Beta; IL6ST Nirs Variant 5; Membrane Glycoprotein 130; IL6ST Nirs Variant 2; IL-6RB; IL6ST Nirs Variant 3; Oncostatin-M Receptor Subunit Alpha; IL6ST Nirs Variant 6; Interleukin-6 Signal Transducer; IL6ST Nirs Variant 1; SGP130; IL-6R-Beta; GP130; CDW130; CD130; HIES4A; Gp130, Oncostatin M Receptor; HIES4B; IL-6 Receptor Subunit Beta; CDw130; IL-6R Subunit Beta; HIES4; CD130 Antigen; IMD94; Gp130 Of The Rheumatoid Arthritis Antigenic Peptide-Bearing Soluble Form; STWS2; Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor); Gp130; Interleukin 6 Signal Transducer
-
AA Sequence
ELLDPCGYISPESPVVQLHSNFTAVCVLKEKCMDYFHVNANYIVWKTNHFTIPKEQYTIINRTASSVTFTDIASLNIQLTCNILTFGQLEQNVYGITIISGLPPEKPKNLSCIVNEGKKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDTPTSCTVDYSTVYFVNIEVWVEAENALGKVTSDHINFDPVYKVKPNPPHNLSVINSEELSSILKLTWTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIRCMKEDGKGYWSDWSEEASGITYEDRPSKAPSFWYKIDPSHTQGYRTVQLVWKTLPPFEANGKILDYEVTLTRWKSHLQNYTVNATKLTVNLTNDRYLATLTVRNLVGKSDAAVLTIPACDFQATHPVMDLKAFPKDNMLWVEWTTPRESVKKYILEWCVLSDKAPCITDWQQEDGTVHRTYLRGNLAESKCYLITVTPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVLEWDQLPVDVQNGFIRNYTIFYRTIIGNETAVNVDSSHTEYTLSSLTSDTLYMVRMAAYTDEGGKDGPEFTFTTPKFAQGEI
-
Predicted Molecular Mass
68.4 kDa
-
Molecular Weight
Approximately 80-120kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Purity
≥ 90%, as determined by reducing SDS-PAGE.
Product Properties
Solution
Supplied as a 0.22 μm filtered solution of PBS, pH 7.4.
<1 EU/μg, determined by LAL method.
Stored at -80°C for 1 year from date of receipt. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Shipping with dry ice.
Documentation
-
Data Sheet (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cao Y, et al. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Sci Rep. 2016 Dec 5;6:38364. [Content Brief]
[2]. Nogueira-Silva C, et al. The role of glycoprotein 130 family of cytokines in fetal rat lung development. PLoS One. 2013 Jun 24;8(6):e67607. [Content Brief]
[3]. Xu S, et al. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013 Nov;17(11):1303-28. [Content Brief]
[4]. Boettger MK, et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther. 2010;12(4):R140. [Content Brief]
[5]. Hong J, et al. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep. 2016 Apr 15;6:24397. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
